Literature DB >> 22999080

Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.

Alexander T Falk1, Michel Poudenx, Josiane Otto, Hannah Ghalloussi, Jérôme Barrière.   

Abstract

Few descriptions of miliary brain metastases have been reported. We report the case of an adenocarcinoma of the lung associated with metachronous miliary brain and lung metastases with an echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) gene translocation. The patient was treated with crizotinib and showed a twelve-month progression-free survival. Clinicians should be attentive of the evolution of brain metastases with patients presenting EML4-ALK translocation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999080     DOI: 10.1016/j.lungcan.2012.08.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report.

Authors:  Ryota Otoshi; Akimasa Sekine; Koji Okudela; Takuma Katano; Masato Asaoka; Satoshi Ikeda; Tomohisa Baba; Shigeru Komatsu; Eri Hagiwara; Ogura Takashi
Journal:  Mol Clin Oncol       Date:  2020-05-04

2.  Molecular subtyping of brain metastases and implications for therapy.

Authors:  Jaclyn J Renfrow; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2013-12

3.  Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.

Authors:  Akimasa Sekine; Takuma Katano; Tsuneyuki Oda; Satoshi Ikeda; Tae Iwasawa; Hiroaki Satoh; Toshiro Kataoka; Koji Okudela; Takashi Ogura
Journal:  Mol Clin Oncol       Date:  2018-10-01

4.  Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.

Authors:  Yang Fu; Yuan Tang; Yue Zheng; Yue-Yun Chen; Ye Hong; Pei-Pei Wang; Qing Li; Ting Liu; Zhen-Yu Ding
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

5.  Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

Authors:  Kimberley S Mak; Justin F Gainor; Andrzej Niemierko; Kevin S Oh; Henning Willers; Noah C Choi; Jay S Loeffler; Lecia V Sequist; Alice T Shaw; Helen A Shih
Journal:  Neuro Oncol       Date:  2014-07-22       Impact factor: 12.300

Review 6.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

7.  Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.

Authors:  Puyuan Xing; Shouzheng Wang; Xuezhi Hao; Tongtong Zhang; Junling Li
Journal:  Oncotarget       Date:  2016-12-20

8.  Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer.

Authors:  Alessandro Russo; Tindara Franchina; Giuseppina Rosaria Rita Ricciardi; Caterina Fanizza; Antonino Scimone; Giuseppe Chiofalo; Antonio Giordano; Vincenzo Adamo
Journal:  Oncotarget       Date:  2017-01-31

Review 9.  Systemic treatment of non-small cell lung cancer brain metastases.

Authors:  Ida Cedrych; Maksymilian A Kruczała; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

10.  Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma.

Authors:  Hironori Satoh; Yusuke Okuma; Jumpei Kashima; Aya Konnno-Yamamoto; Yasushi Yatabe; Yuichiro Ohe
Journal:  Onco Targets Ther       Date:  2021-04-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.